Replies to post #197615 on Biotech Values

[DewDiligence]

CHRS has Humira and Enbrel FoBs in the pipeline in addition to Neulasta FoB. What fraction of their value derives from Neulasta FoB expectations?

Hard to say. My comments in #msg-118704629 have more to do with questioning management's credibility than with the value of the Neulasta program per se.